Abstract
Controversy remains about the off label use of bevacizumab The era of biological agents for the management of neovascular age related macular degeneration was firmly ushered in when two randomised...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
